Using AI to screen infants for hip dysplasia
Artificial Intelligence Augmented Ultrasound for Developmental Dysplasia of the Hip: a Validity Study
This study is testing if using AI with ultrasounds can help doctors find hip dysplasia in infants better than regular ultrasounds.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 4 Weeks to 20 Weeks |
| Sex | All |
| Sponsor | Murdoch Childrens Research Institute Academic / other |
| Locations | 1 site (Parkville, Victoria) |
| Trial ID | NCT06647225 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the accuracy of an artificial intelligence-enhanced ultrasound in screening for developmental dysplasia of the hip (DDH) in infants. Researchers will compare the results of AI-assisted ultrasounds with standard ultrasound measures to determine if the AI approach can improve detection rates. Additionally, the study will gather feedback from parents regarding their experiences with the ultrasound procedure. Participants will undergo an extra ultrasound during their scheduled appointment and complete a questionnaire about the process.
Who should consider this trial
Good fit: Ideal candidates for this study are infants aged 4-20 weeks who are attending The Royal Children's Hospital for a potential diagnosis of hip dysplasia.
Not a fit: Patients currently receiving treatment for hip dysplasia will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and accessible screening for hip dysplasia in infants, potentially reducing the number of undetected cases.
How similar studies have performed: While some studies have explored AI in medical imaging, this specific application for hip dysplasia screening is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Enrolled in the VicHip study * Is 4-20 weeks of age at enrolment * Is attending The Royal Children's Hospital for the purpose of the potential diagnosis of DDH * Has a diagnostic (standard) hip ultrasound on the day of their out-patient appointment * Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf. Exclusion Criteria: Participants will be excluded from enrolment if: • They are currently receiving treatment for DDH
Where this trial is running
Parkville, Victoria
- Royal Children's Hospital — Parkville, Victoria, Australia (Recruiting)
Study contacts
- Principal investigator: Leo T Donnan — Murdoch Childrens Research Institute
- Study coordinator: Natalie K Hyde, BBiomedSc (Hons), PhD
- Email: natalie.hyde@mcri.edu.au
- Phone: 61 3 9936 6246
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.